Additionally, one presentation will feature BOT/BAL and invariant natural killer T cells (iNKTs) in patients with refractory gastric cancer. "These presentations will highlight BOT/BAL's potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback